RX Review: Updates in Pediatric Food Allergy and Anaphylaxis for 2025 - Episode 5
In this video, part 5 of a 5-part series, panelists discuss emerging innovations in food allergy and anaphylaxis research poised to reshape clinical practice.
In this HCPLive and Contemporary Pediatrics RX Review Special Report, Brian Schroer, MD, moderates a forward-looking discussion with Colleen Kraft and Russell Traister on emerging innovations in food allergy and anaphylaxis research poised to reshape clinical practice.
Traister highlights the potential of novel therapies, including patch-based immunotherapy and the combination of biologics like omalizumab (Xolair) with oral immunotherapy (OIT). He raises key questions about how these therapies might be sequenced or combined to optimize treatment.
Kraft emphasizes the promise of these treatments not only for food allergy but also for related allergic conditions like asthma and atopic dermatitis, offering broader benefits for children and their families. She also notes the accessibility challenges, acknowledging that while OIT may be less costly than biologics, its time-intensive nature makes it less feasible for primary care settings—posing barriers to care.
Schroer points to the growing momentum around early immunotherapy, especially for young children under four, which shows potential for raising allergy thresholds and, in some cases, helping children outgrow allergies altogether. He also highlights the need for improved implementation of early allergen introduction strategies.
The panel closes by stressing that advances in food allergy care have far-reaching impacts—helping children attend school, parents return to work, and families live with less anxiety over severe allergic reactions.
Part 1: RX Review: Advances in Pediatric Food Allergy and Anaphylaxis Management
Part 2: RX Review: Addressing Unmet Needs in Pediatric Food Allergy Research
Part 3: RX Review: Needle-Free Epinephrine and Emerging Food Allergy Treatments
Part 4: RX Review: Closing Gaps in Clinician Education on Food Allergies
Our Panelists:
Brian Schroer, MD, is an allergist immunologist at the Cleveland Clinic Children's Hospital. Board-certified in internal medicine, pediatrics, and allergy and immunology, Schroer serves as the moderator for this panel discussion.
Colleen Kraft, MD, is a clinical professor of Pediatrics at the Keck School of Medicine of USC and an attending physician at the Children’s Hospital Los Angeles. In addition to these roles, Kraft is also the former president of the American Academy of Pediatrics.
Russell Traister, MD, is a pediatric allergy and immunology specialist at Allegheny Health Network’s Pediatric Institute. Board-certified in allergy, immunology, and internal medicine, Traister serves as the third panelist for our discussion.
Relevant disclosures for Schroer include Genzyme, AstraZeneca, Amgen, GSK, and Sobi. Relevant disclosures for Kraft include Sanofi and Sobi. Relevant disclosures for Traister include Abbvie.
